Abstract Treatment with the antimalarial drug hydroxychloroquine (HCQ) has been
associated with reduced risk of thrombosis in the antiphospholipid (aPL) syndrome (APS) …

Prothrombotic properties of antiphospholipid (aPL) antibodies may be explained in part by
their ability to enhance the activation of platelets pre-treated with low doses of ADP or …

Background Previous studies have demonstrated that human monoclonal and polyclonal
anticardiolipin antibodies have thrombogenic properties in vivo. Using such a model in …

Antiphospholipid syndrome (APS) is an autoimmune prothrombotic disorder associated with
autoantibodies to phospholipid (PL)–binding proteins, such as β2-glycoprotein I (β2GPI). We …

It has been shown that endothelial cell (EC) activation and tissue factor (TF) upregulation in
EC and monocytes by antiphospholipid antibodies (aPL Abs) leads to a prothrombotic state …

Anti-phospholipid (aPL) antibodies that exhibit binding in cardiolipin (CL) ELISA can be
purified to greater than 95% purity by sequential phospholipid affinity and ion-exchange …

Placental ischemic disease and adverse pregnancy outcomes are frequently observed in
patients with antiphospholipid syndrome (APS). Despite the administration of conventional …

L UPUS ANTICOAGULANTS, and “antiphospholipid” autoantibodies in general, are of
considerable clinical importance because of their strong association with thrombosis …

Utilizing this unique animal model of thrombosis we demonstrated that human (IgG, IgM or
IgA) polyclonal and monoclonal antiphospholipid antibodies derived from APS patients have …

The phospholipid-binding plasma protein β2-glycoprotein I (β2-GPI) is the primary antigen
recognized by the circulating autoantibodies in patients with the" anti-phospholipid …